Middle East and Africa PCSK9-Targeted Therapy Market Size, Share & Trends Analysis Report By Drug Type / Modality (Monoclonal Antibodies (mAbs) Alirocumab Evolocumab, siRNA-based Therapies Inclisiran, Gene Editing and Other Novel Modalities CRISPR-based approaches Antisense oligonucleotides (ASOs) ), By Indication  (Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), Homozygous Familial Hypercholesterolemia (HoFH), Hyperlipidemia (Non-FH) ), By Country (Brazil, Mexico, Argentina, Chile, Colombia) and Forecast, 2026-2034

Middle East and Africa PCSK9-Targeted Therapy Market Trends

Long-Acting LDL-C Suppression and Next-Generation Modalities Reshape Treatment

PCSK9 treatment is shifting from frequent injectable antibody administration toward durable RNA-silencing and potentially one-time gene-editing approaches. Monoclonal antibodies such as evolocumab and alirocumab can reduce LDL-C by around 60%, while inclisiran delivers comparable LDL-C lowering through twice-yearly maintenance dosing. In regional diabetes populations, 92% had dyslipidemia, 77% were receiving statins, and median LDL-C remained 85 mg/dL, illustrating persistent residual treatment requirements despite substantial conventional therapy use.

Clinical demand is increasingly concentrated among very-high-risk ASCVD, familial hypercholesterolemia and statin-intolerant populations. Across 4,378 Africa-Middle East participants, 39% qualified for statin treatment under ACC/AHA criteria versus 24% under older NCEP-ATP recommendations, a 63% increase. Among adults aged 65 years or older, eligibility reached 86%, reinforcing the large population funnel potentially progressing toward combination lipid-lowering regimens when LDL-C goals remain unmet.

Middle East and Africa PCSK9-Targeted Therapy Market Drivers

High Dyslipidemia Burden and Persistent LDL-C Treatment Gaps Accelerate Advanced Therapy Utilization

The major demand catalyst is the region's substantial cardiovascular-risk burden. Dyslipidemia affected approximately 70% of outpatients in the ACE cohort, while 79% of high-risk patients were not at LDL-C goals. In Saudi Arabia specifically, dyslipidemia reached 68.6% in an ACE analysis, while nearly 49.8% of participants carried more than 3 cardiovascular risk factors. PCSK9 antibodies can lower LDL-C by approximately 60%, creating a clinically relevant escalation option for patients inadequately controlled with statins and ezetimibe.

Middle East and Africa PCSK9-Targeted Therapy Market Restraints

High Treatment Costs and Access Barriers Restrict Broader Patient Penetration

Affordability remains a significant restraint, particularly where reimbursement for specialty cardiovascular drugs is limited. A Saudi multicenter analysis covering 118 PCSK9-treated patients and 304 statin-plus-ezetimibe patients estimated annual PCSK9 inhibitor costs of approximately USD 4,024–7,559. PCSK9 therapy produced a mean LDL-C reduction of 1.432 mmol/L versus 0.644 mmol/L with statins plus ezetimibe, but acquisition costs remain an important access consideration.

Middle East and Africa PCSK9-Targeted Therapy Market Opportunities

Earlier Combination Therapy Creates Expansion Potential Across High-Risk Cardiovascular Populations

Treatment intensification provides substantial commercial opportunity. In the PACT-MEA population of 3,726 individuals with type 2 diabetes, 98% had coronary risk factors, 84% had at least 2 risk factors, 92% had dyslipidemia and 20.9% had established ASCVD. Saudi guidance increasingly supports early integration of PCSK9-targeted agents for selected high- and very-high-risk patients failing to reach LDL-C targets, expanding the potential treatment funnel beyond late-line use.

Challenges in Middle East and Africa PCSK9-Targeted Therapy Market

Diagnosis, LDL-C Goal Attainment and Treatment Continuity Remain Uneven

Clinical infrastructure and treatment continuity remain uneven across heterogeneous healthcare systems. Africa-Middle East evidence showed only 16% of outpatients using prior lipid-altering drugs despite approximately 70% dyslipidemia prevalence. Among high-risk patients, 79% were outside LDL-C goals, while Saudi evidence indicates LDL-C goal attainment of only 12% among high-risk and 3% among very-high-risk populations, emphasizing diagnosis-to-treatment gaps that can constrain advanced therapy uptake.

Middle East and Africa PCSK9-Targeted Therapy Market Segmentation

The industry is segmented by drug type/modality, indication, route of administration, distribution channel and patient type. Within the supplied quantitative modality dataset, monoclonal antibodies account for approximately 48.45% of 2026 revenue, followed by siRNA-based therapies at 30.50% and gene editing/other novel modalities at 21.05%.

By Drug Type / Modality

Monoclonal antibodies, comprising alirocumab and evolocumab, form the largest quantified subsegment, increasing from USD 536.16 million in 2025 to USD 591.92 million in 2026 and USD 1,306.22 million by 2034 at a 10.40% CAGR. Their 2026 contribution is approximately 48.45% of the supplied modality total.

Gene editing and other novel modalities, including CRISPR-based approaches and ASOs, are the fastest-growing quantified category at an 11.13% CAGR, compared with 10.99% for siRNA therapies. siRNA revenue increases from USD 372.60 million in 2026 to USD 858.06 million by 2034.

By Indication

Segmentation includes HeFH, ASCVD, HoFH and non-FH hyperlipidemia. ASCVD represents a central clinical application because PCSK9 therapies are positioned for patients with established disease or very high cardiovascular risk whose LDL-C remains inadequately controlled. Numerical market values and CAGRs by indication were not supplied and therefore are not extrapolated.

HeFH and HoFH remain important genetically defined populations, while non-FH hyperlipidemia broadens the addressable pool. No indication-level fastest-growing CAGR was provided in the mandatory dataset.

By Route of Administration

Subcutaneous injection covers major marketed antibody and siRNA therapies, while intravenous injection and oral pipeline approaches represent additional development pathways. No route-specific revenue, percentage contribution or CAGR was supplied, preventing unsupported numerical allocation.

The long-term route mix could evolve as less-frequent dosing and pipeline alternatives progress; however, no fastest-growing route CAGR is assigned without supplied quantitative evidence.

By Distribution Channel

Hospital pharmacies, retail pharmacies and online pharmacies constitute the defined channels. Specialty prescribing, reimbursement management and physician-led initiation support hospital-oriented dispensing, but no channel-level market values or CAGR figures were supplied.

Retail and online channels may participate in maintenance access depending on national dispensing rules. Quantitative dominance or fastest-growing channel claims cannot be established from the mandatory dataset.

By Patient Type

Patient segmentation comprises primary prevention, secondary prevention and statin-intolerant patients. Secondary prevention is clinically important because established ASCVD substantially elevates cardiovascular risk; however, no patient-type revenue split or CAGR was provided.

Primary-prevention high-risk patients and statin-intolerant patients provide additional treatment pools. No fastest-growing patient category is numerically designated because the supplied tables do not contain patient-level forecasts.

Middle East and Africa PCSK9-Targeted Therapy Market Counties Outlook

The specified country-outlook list—Brazil, Mexico, Argentina, Chile and Colombia—does not correspond to the Middle East and Africa geography and none of these countries appears in the supplied mandatory dataset. Accordingly, regional revenue, shares, CAGR, production numbers or sector splits for these five countries cannot be presented without fabricating data.

Within the supplied geography, the UAE contributes approximately 40.04% of the USD 1,220.64 million 2026 country total, followed by Saudi Arabia at 28.95%, South Africa at 9.44%, Egypt at 8.72%, Turkey at 7.83% and Nigeria at 5.02%. By 2034, the respective supplied forecasts are USD 1,076.21 million, USD 792.43 million, USD 266.99 million, USD 244.44 million, USD 221.19 million and USD 140.92 million.

Top players in Middle East and Africa PCSK9-Targeted Therapy Market

• Amgen Inc.
• Sanofi
• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca plc
• Eli Lilly and Company
• Pfizer Inc.
• Ionis Pharmaceuticals, Inc.
• Silence Therapeutics plc
• Alnylam Pharmaceuticals, Inc.
• Verve Therapeutics, Inc.

Top Two Companies

• Amgen Inc.

Amgen occupies a major competitive position through evolocumab, a monoclonal antibody used for intensive LDL-C reduction in high-risk patients. PCSK9 antibodies can lower LDL-C by around 60%, supporting their use alongside maximally tolerated lipid-lowering therapy. Exact Middle East and Africa company revenue share percentages were not supplied and are therefore not fabricated.

• Novartis AG

Novartis is differentiated through inclisiran and its siRNA mechanism, offering sustained PCSK9 suppression with twice-yearly maintenance administration. Clinical guidance describes LDL-C reductions broadly comparable with PCSK9 antibodies, while the less-frequent dosing model can address adherence requirements. Exact regional company percentage share was not provided in the mandatory data.

Recent Developments in Middle East and Africa PCSK9-Targeted Therapy Market

• 2026:The Saudi Heart Association published a position statement supporting targeted early integration of PCSK9-directed treatments—including evolocumab, alirocumab and inclisiran—for appropriate high- and very-high-risk patients.
• 2026:Saudi guidance highlighted approximately 60% LDL-C lowering from PCSK9 monoclonal antibodies and comparable LDL-C reduction from twice-yearly inclisiran.
• 2026:A MENA meta-analysis incorporated 116 representative studies covering 628,134 individuals, strengthening evidence around the region's dyslipidemia burden.
• 2025:Saudi cardiovascular-prevention guidance recommended adding PCSK9 monoclonal antibodies for very-high-risk FH patients failing LDL-C targets despite high-intensity statin plus ezetimibe therapy.
• 2025:A Saudi historical cohort involving 118 PCSK9-treated patients reported greater LDL-C reduction and fewer cardiovascular-related hospitalizations than the 304-patient statin-plus-ezetimibe comparator cohort, while highlighting annual acquisition costs of roughly USD 4,024–7,559.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 forming the historical framework. Mandatory supplied values were retained as the primary quantitative source: the country dataset advances from USD 1,103.21 million in 2025 to USD 1,220.64 million in 2026 and USD 2,742.18 million in 2034 at an 11% CAGR. The separate modality dataset totals USD 1,103.22 million, USD 1,221.62 million and USD 2,762.35 million for those years; its minor difference from the country dataset has been preserved rather than normalized. Calculated percentage contributions use the corresponding supplied table total, while unsupported regional, segment, company-share, production-volume and CAGR figures have not been fabricated.